Literature DB >> 17086064

A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.

Karine Lacombe1, Aurélie Ollivet, Joel Gozlan, Sandra Durantel, Nathalie Tran, Pierre-Marie Girard, Fabien Zoulim.   

Abstract

A molecular virology analysis performed in an HIV-hepatitis B virus (HBV) co-infected patient showed the emergence of an unusual HBV polymerase gene mutation (rt A181T) under adefovir therapy, conferring resistance to adefovir but not to tenofovir, as proved by in-vitro phenotypic analysis. This observation suggests that careful monitoring of co-infected patients is required to diagnose HBV resistance to nucleos(t)ide analogues, and that tenofovir may be active at least against some of the adefovir-resistant strains.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17086064     DOI: 10.1097/01.aids.0000252061.35422.84

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

Review 1.  Antiviral therapies: focus on hepatitis B reverse transcriptase.

Authors:  Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

2.  Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B.

Authors:  Sang-Hoon Ahn; Young-Oh Kweon; Seung-Woon Paik; Joo-Hyun Sohn; Kwan-Sik Lee; Dong Joon Kim; Teerha Piratvisuth; Man Fung Yuen; Anuchit Chutaputti; You-Chen Chao; Aldo Trylesinski; Claudio Avila
Journal:  Hepatol Int       Date:  2011-10-12       Impact factor: 6.047

Review 3.  Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?

Authors:  David Durantel
Journal:  Antivir Ther       Date:  2010

Review 4.  Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.

Authors:  Chloe L Thio
Journal:  Antivir Ther       Date:  2010

5.  Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.

Authors:  Karine Lacombe; Joël Gozlan; Anders Boyd; Pierre-Yves Boelle; Philippe Bonnard; Jean-Michel Molina; Patrick Miailhes; Caroline Lascoux-Combe; Lawrence Serfaty; Fabien Zoulim; Pierre-Marie Girard
Journal:  Antivir Ther       Date:  2008

6.  Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation.

Authors:  Vignan Manne; Ruby M Allen; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-03

7.  Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.

Authors:  Marina B Klein; Jean-Guy Baril; Marc-André Charron; Claude Fortin; Richard Lalonde; Marie-France Matte; Marc Poliquin; Annie Talbot; Rachel Therrien; Cécile Tremblay; Benoît Trottier; Irina Tsarevsky; Jean-Pierre Villeneuve
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

8.  Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Chau-Ting Yeh; Tiffany Chen; Chao-Wei Hsu; Yi-Cheng Chen; Ming-Wei Lai; Kung-Hao Liang; Tse-Ching Chen
Journal:  BMC Cancer       Date:  2011-09-21       Impact factor: 4.430

9.  Antiviral treatment of chronic hepatitis B virus (HBV) infections.

Authors:  Erik De Clercq; Geoffrey Férir; Suzanne Kaptein; Johan Neyts
Journal:  Viruses       Date:  2010-05-31       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.